Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

Authors: Kelly E Seaton, Carmen A Paez, Chenchen Yu, Shelly T Karuna, Theresa Gamble, Maurine D Miner, Jack Heptinstall, Lu Zhang, Fei Gao, Margaret Yacovone, Hans Spiegel, Julie B Dumond, Maija Anderson, Estelle Piwowar-Manning, Bonnie Dye, India Tindale, Lori Proulx-Burns, Meg Trahey, Simbarashe Takuva, Azwidihwi Takalani, Veronique C Bailey, Spyros A Kalams, Hyman Scott, Nonhlanhla N Mkhize, Joshua A Weiner, Margaret E Ackerman, M Juliana McElrath, Michael Pensiero, Dan H Barouch, David Montefiori, Georgia D Tomaras, Lawrence Corey, Myron S Cohen, Yunda Huang, Sharana Mahomed, Marc Siegel, Colleen F Kelley

Published: 2025-05-27

DOI: 10.1016/s2352-3018(25)00012-8

Source: Full article

---

Abstract

No abstract found.